An evaluation of the drug-drug interaction between proton-pump inhibitors and EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients.

被引：0
|
作者：
Chan, Alexandre
Chen, Bingrong
Ng, Raymond [2 ]
Yong, Wei-Peng [1 ]
Ko, Yu
机构：
[1] Natl Univ Singapore, Inst Canc, Singapore 117548, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：E221 / E222
页数：2
相关论文
共 50 条
  • [41] Resistance in EGFR-specific tyrosine kinase inhibitors in Non-Small Lung Cancer cell lines
    Orth, F.
    Schaefer, B.
    Harsch, A.
    Weller, S.
    Beigl, T.
    Barber, L.
    Kopp, H. -G
    Essmann, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 228 - 228
  • [42] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
  • [43] Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Hui
    Hu, Qianfan
    Chen, Yuzhong
    Huang, Xing
    Feng, Yipeng
    Shi, Yuanjian
    Li, Rutao
    Yin, Xuewen
    Song, Xuming
    Liang, Yingkuan
    Zhang, Te
    Xu, Lin
    Dong, Gaochao
    Jiang, Feng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [44] Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Rouge, Thibault de La Motte
    Valent, Alexander
    Ambrosetti, Damien
    Vielh, Philippe
    Lacroix, Ludovic
    ANNALES DE PATHOLOGIE, 2007, 27 (05) : 353 - 363
  • [45] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [46] The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
    Buti, Sebastiano
    Tommasi, Chiara
    Scartabellati, Giulia
    De Giorgi, Ugo
    Brighi, Nicole
    Rebuzzi, Sara Elena
    Puglisi, Silvia
    Caffo, Orazio
    Kinspergher, Stefania
    Mennitto, Alessia
    Cattrini, Carlo
    Santoni, Matteo
    Verzoni, Elena
    Rametta, Alessandro
    Stellato, Marco
    Malgeri, Andrea
    Roviello, Giandomenico
    de Filippo, Massimo
    Cortellini, Alessio
    Bersanelli, Melissa
    ANTI-CANCER DRUGS, 2023, 34 (01) : 178 - 186
  • [47] Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Chang, Hyun
    Zhang, Xianglan
    Kim, Da Rae
    Kim, Gun Min
    Kim, Se Hyun
    Kim, Joo-Hang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [49] Treatment of Non-Small Cell Lung Cancer Patients in the Intensive Care Units with EGFR-Tyrosine Kinase Inhibitors
    Lee, I.
    Yang, C.
    Shih, J.
    Yu, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [50] Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Kim, Soomin
    Koh, Jaemoon
    Kim, Tae Min
    Oh, Songji
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    ISCIENCE, 2025, 28 (02)
12345